Format

Send to

Choose Destination
See comment in PubMed Commons below
Neurology. 1993 Aug;43(8):1609-11.

Clinical trial of indomethacin in Alzheimer's disease.

Author information

1
L.J. Roberts Center for Alzheimer's Research, Sun Health Research Institute, AZ 85372.

Abstract

In a 6-month, double-blind, placebo-controlled study, 100 to 150 mg/d indomethacin appeared to protect mild to moderately impaired Alzheimer's disease patients from the degree of cognitive decline exhibited by a well-matched, placebo-treated group. Over a battery of cognitive tests, indomethacin patients improved 1.3% (+/- 1.8%), whereas placebo patients declined 8.4% (+/- 2.3%)--a significant difference (p < 0.003). Caveats include adverse reactions to indomethacin and the limited scale of the trial.

PMID:
8351023
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Support Center